Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 5/20 | 0.46 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936014 | 1.00 | VNN1 (0.46) | VNN1MAP2K4EGFRPOLBNR2F2 | |
| SCHEMBL30000151 | 0.82 | PTK2 (0.49) | VNN1MAP2K4EGFRPOLBNR2F2 | |
| SCHEMBL26131177 | 0.77 | CDK1 (0.47) | VNN1MAP2K4EGFRPOLBNR2F2 | |
| SCHEMBL19407673 | 0.77 | VNN1 (0.56) | VNN1EGFRPOLBNR2F2CDK1 | |
| SCHEMBL30661275 | 0.75 | CCNE2 (0.55) | VNN1EGFRPOLBNR2F2CDK1 | |
| SCHEMBL7170316 | 0.75 | APP (0.50) | MAP2K4EGFRPOLBNR2F2THRB | |
| SCHEMBL29133952 | 0.75 | CCNE2 (0.55) | VNN1EGFRPOLBNR2F2CDK1 | |
| SCHEMBL17011498 | 0.73 | MAPT (0.47) | VNN1MAP2K4EGFRPOLBNR2F2 | |
| SCHEMBL21046947 | 0.72 | VNN1 (0.64) | VNN1HDAC6THRBMEN1KMT2A | |
| SCHEMBL25934362 | 0.72 | VNN1 (0.64) | VNN1HDAC6THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2024-10-03 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117500803-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | VNN1 3647/4885MAP2K4 2852/4885EGFR 1/4885 |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | VNN1 3165/4885MAP2K4 1965/4885EGFR 1/4885 |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | VNN1 3165/4885MAP2K4 1965/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.